BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
BioMarin Announces Second Quarter 2015 Financial Results and Company Update
August 3, 2015 4:02 PM EDT- In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/Y - First Patients Enrolled in 4th Cohort of Phase 2 Study of Vosoritide for the Treatment of Achondroplasia
Financial Highlights ($ in millions, except per share data, unaudited)
 Three Months Ended June 30, Six Months Ended June 30,  2015 2014 % Change 2015 2014 % Change        Total BioMarin Revenue  $ 250.5  $ 191.8 31%  $ 453.8  $ 343.3 32% Vimizim Net Product Revenue  53.9  14.3 n.m.  104.5... More